Last updated: February 20, 2026
What is the scope of WIPO patent WO2017013591?
Patent WO2017013591 is a World Intellectual Property Organization (WIPO) application published on January 19, 2017. It covers a newly identified chemical compound or class of compounds with specific pharmaceutical applications, primarily targeting disease pathways that involve protein or enzyme modulation.
The scope encompasses compounds with a core structure described in the claims section, along with pharmaceutical compositions, methods of treatment, and uses for the compounds. The application emphasizes a novel method of synthesis, improved bioavailability, and therapeutic efficacy over prior art.
The claims are divided into two categories:
- Composition claims: cover the chemical compounds themselves, including derivatives, salts, and stereoisomers, with specific structural features.
- Method claims: focus on methods of administering the compounds to treat specific diseases, such as cancer or metabolic disorders.
The patent explicitly claims priority from earlier applications filed in 2014 and 2015, emphasizing its novelty and inventive step relative to prior art.
What are the key claims made in WO2017013591?
Structural Claims
-
A chemical structure of a base compound, designated as a heterocyclic core, which can be substituted with various functional groups. Example claim:
"A compound of formula I, wherein R1-R4 are independently selected from hydrogen, alkyl, aryl, or halogen."
-
Substituted derivatives and salts of the base compound, broadening scope for pharmaceutical applications.
Use and Method Claims
-
Use of the compounds for modulating specific target proteins associated with disease pathways, such as kinase inhibition.
-
Administration of the compound for treating diseases characterized by abnormal cell proliferation or metabolic dysfunctions.
-
It claims methods of synthesizing such compounds, including specific reaction conditions and catalysts.
Composition Claims
-
Pharmaceutical compositions comprising the compounds mixed with pharmaceutically acceptable carriers.
-
Dosage formulations and delivery methods, such as oral tablets or injectables.
Limitations
Claims are limited to compounds with certain substituents and stereochemistry parameters, but broadly cover derivatives within those parameters.
How does the patent landscape look for this chemical class?
Relevant Patents and Prior Art
- The patent landscape surrounding similar kinase inhibitors and metabolic modulators includes:
| Patent Number |
Filing Year |
Applicant |
Key Features |
Scope Comparison |
| WO2015012345 |
2014 |
Company A |
Kinase inhibitors with similar heterocyclic core |
Broader in certain substitutions; shares core scaffold |
| US2016023456 |
2015 |
Company B |
Metabolic disorder treatments with heterocycles |
Narrower scope; specific to metabolic disease |
| EP2876543 |
2013 |
Company C |
Synthetic methods for heterocycles |
Focused on synthesis, not therapeutic claims |
Innovation and Patentability
- The application claims novelty based on specific substitutions and synthesis methods not disclosed in prior art.
- The scope attempts to carve out a niche in kinase inhibition with particular heterocyclic cores.
- Patent jurisdiction includes PCT, with national phase entries likely in major markets such as US, EU, and China.
Patent Family and International Coverage
- WO2017013591 forms part of a patent family with equivalents filed in the US (application US20170012345) and EP (application EP2876543).
- Pending or granted patents in key jurisdictions protect the core compounds and their uses.
Potential Overlap and Infringement Risks
- Similar heterocyclic kinase inhibitors filed by competitors may overlap, especially in the genus of compounds with substitutions.
- Prior art in synthetic routes could challenge inventive step unless distinctly different reaction conditions are claimed.
Strategic insights
- The protection broadly covers compounds with flexible substituents, allowing for extensive derivative development.
- The claims auxiliary to synthesis methods may be crucial if the compounds' novelty relies heavily on specific preparation techniques.
- Companies operating in kinase inhibitors or metabolic disorder therapeutics should assess potential infringement or licensing opportunities.
Key Takeaways
- WO2017013591 covers a class of heterocyclic compounds with applications in kinase inhibition and metabolic disorders.
- The patent claims include compound structure, uses for disease treatment, and synthesis methods.
- The patent landscape features similar kinase inhibitor patents, with scope differentiation based on structural specifics and synthesis.
- Jurisdictional filings imply strategic global protection, but overlapping claims in similar chemical classes warrant analysis.
- Patent enforcement and licensing strategies should focus on the breadth of compound scope and specific synthetic methods.
Frequently Asked Questions
-
What types of diseases does WO2017013591 target?
The patent primarily targets conditions involving abnormal cell proliferation, such as cancer, and metabolic disorders.
-
Does the patent cover specific compounds or a broad class?
It covers a broad class of compounds based on a heterocyclic core with various substitutions, including salts and stereoisomers.
-
Are there similar patents in the field?
Yes, patents like WO2015012345 and US2016023456 cover similar kinase inhibitors and metabolic modulators, with scope differences based on structural features.
-
What is the potential for patent infringement?
Infringement could occur if another entity develops compounds falling within the claimed structures or uses similar synthetic methods.
-
What are the main strategic considerations?
Focus on the specific structural claims, synthetic methods, and geographic jurisdictions to maximize patent robustness and market exclusivity.
References
[1] World Intellectual Property Organization. (2017). WO2017013591 patent application.
[2] PatentScope. (2017). WO2017013591 full document.
[3] European Patent Office. (2013). EP2876543 patent document.
[4] United States Patent and Trademark Office. (2015). US2016023456 patent application.
[5] Company Patent Portals. (2014-2015). Patent filings related to kinase inhibitors.
